



ProCare Rx

in focus

VOL. 6 ISSUE 1 2009

Formulary News

Recent Additions to the formulary

CLINICAL CATEGORY	BRAND NAME Generic name	Dosage form	INDICATIONS	FORMULARY PLACEMENT
Anticonvulsants	divalproex sodium	250mg, 500mg ER tablets; 125mg sprinkle caps	Seizure disorders	Tier 1
Gastrointestinal Agents	KAPIDEX® dexlansoprazole	30mg, 60mg capsules	Gastroesophageal Reflux Disease	Tier 3
Gout & Hyperuricemia Agents	ULORIC® febuxostat	40mg, 80mg tabs	Hyperuricemia in patients with gout	Tier 3
Hematologic Agents	PROMACTA® eltrombopag olamine	25mg, 50mg tabs	Management of thrombocytopenia	Specialty
Topical Agents	ACANYA® clindamycin/benzoyl peroxide	1.2%/2.5% gel	Acne vulgaris	Tier 3
	VECTICAL® calcitriol	3 mcg/gm ointment	Plaque psoriasis	Tier 3
Urological Agents	RAPAFLO® silodosyn	4mg, 8mg capsules	Benign prostatic hyperplasia	Tier 3
	TOVIAZ® fesoterodine fumarate	4mg, 8mg tablets	Overactive bladder	Tier 3

Medications moved to **NON-PREFERRED (Tier 3)** status (effective 5/1/2009)

Member will pay a **non-preferred copay**

CLINICAL CATEGORY	BRAND NAME NON-PREFERRED	ROUTE	INDICATIONS	BRAND NAME PREFERRED
Anticonvulsants	DEPAKOTE ER® divalproex sodium	Oral	Seizure disorders	divalproex sodium, Tegretol XR, Dilantin
Gastrointestinal Agents	PROTONIX® SUSPENSION pantoprazole (EFFECTIVE 4/1/09)	Oral	Erosive esophagitis, gastroesophageal reflux, Zollinger-Ellison syndrome	omeprazole, Nexium, Zegerid

P&T NEWS

ProCare PBM's Pharmacy and Therapeutics (P&T) Committee meets on a quarterly basis to review new medications, current protocols, market trends and formulary matters. The Committee is composed of a diverse group of Physicians, Pharmacists and administrators. Current medical literature and FDA-approved materials are used for discussions before final recommendations are made for formulary and benefit plan design implementation.

Authorized Generics NEWS - Authorized Generics are generic products produced by brand companies and marketed under a private label (typically by a generic manufacturer company). In order for a product to be considered as authorized generic, characteristics such as labeling, packaging (other than repackaging), product code, labeler code, trade name must differ from that of the branded drug. In many instances, authorized generics are priced to compete with other generics; however, commonly their cost is as high as their branded counterpart. The P&T Committee has voted in favor of placing new authorized generics on the formulary in the non-preferred tier until additional generic entries result in downward cost pressures.

Gastroesophageal Reflux Disease - To view a brochure about "Gastroesophageal Reflux Disease (GERD)" with helpful information on this subject, click on the hyperlink below or copy and paste the link below into your browser address window:

<http://www.gatewayforhealth.com:80/gateway/viewBrochure.do?key=3289&spread=rs>

Care Focused, Outcomes Driven!